The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Open accessPublished version of a preprint
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant. Structural analysis reveals that the contact residues of the LY-CoV1404 epitope are highly conserved, except for N439 and N501. The binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The broad and potent neutralization activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Twelve years of SAMtools and BCFtools
Danecek, P., Bonfield, J. K., Liddle, J., Marshall, J., Ohan, V., Pollard, M. O., Whitwham, A., Keane, T., McCarthy, S. A., Davies, R. M., et al. (2021) · GigaScience · doi:10.1093/gigascience/giab008 · Cited by 15,343
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,697
GISAID: Global initiative on sharing all influenza data – from vision to reality
Shu, Y., & McCauley, J. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.13.30494 · Cited by 3,039
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Self-citationData processing and analysis with the autoPROC toolbox
Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O., Paciorek, W., Womack, T., & Bricogne, G. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911007773 · Cited by 2,029
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationSARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
Spike mutation D614G alters SARS-CoV-2 fitness
Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558
Self-citationNaldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349
Self-citationStructure-based design of prefusion-stabilized SARS-CoV-2 spikes
Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031364 · Cited by 1,246
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210
Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans
Oude Munnink, B. B., Sikkema, R. S., Nieuwenhuijse, D. F., Molenaar, R. J., Munger, E., Molenkamp, R., van der Spek, A., Tolsma, P., Rietveld, A., Brouwer, M., et al. (2021) · Science · doi:10.1126/science.abe5901 · Cited by 1,117
SARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097 · cited 1×
“It remains unknownwhether vaccines will significantly alter the mutation profile of the virus (Choi et al., 2020; Kemp et al., 2021).”
Self-citationEarly treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107934 · Cited by 1,086
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Yurkovetskiy, L., Wang, X., Pascal, K. E., Tomkins-Tinch, C., Nyalile, T. P., Wang, Y., Baum, A., Diehl, W. E., Dauphin, A., Carbone, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.032 · Cited by 1,025
Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant
Pachetti, M., Marini, B., Benedetti, F., Giudici, F., Mauro, E., Storici, P., Masciovecchio, C., Angeletti, S., Ciccozzi, M., Gallo, R. C., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02344-6 · Cited by 996
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.036 · Cited by 897
Gottlieb, R. L., Nirula, A., Chen, P., Boscia, J., Heller, B., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · JAMA · doi:10.1001/jama.2021.0202 · Cited by 872
Self-citationAntibody evasion properties of SARS-CoV-2 Omicron sublineages
Iketani, S., Liu, L., Guo, Y., Liu, L., Chan, J. F.-W., Huang, Y., Wang, M., Luo, Y., Yu, J., Chu, H., et al. (2022) · Nature · doi:10.1038/s41586-022-04594-4 · Cited by 809
Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.-Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020) · Science · doi:10.1126/science.abc4730 · Cited by 762
Liu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.014 · Cited by 725
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1743767 · Cited by 711
Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628
Self-citationSmart, O. S., Womack, T. O., Flensburg, C., Keller, P., Paciorek, W., Sharff, A., Vonrhein, C., & Bricogne, G. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911056058 · Cited by 612
Thomson, E. C., Rosen, L. E., Shepherd, J. G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj, J. A., Davis, C., Piccoli, L., Pascall, D. J., Dillen, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.037 · Cited by 606
Geographic and Genomic Distribution of SARS-CoV-2 Mutations
Mercatelli, D., & Giorgi, F. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01800 · Cited by 589
Antibody evasion by the P.1 strain of SARS-CoV-2
Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.055 · Cited by 583
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
Jones, B. E., Brown-Augsburger, P. L., Corbett, K. S., Westendorf, K., Davies, J., Cujec, T. P., Wiethoff, C. M., Blackbourne, J. L., Heinz, B. A., Foster, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf1906 · Cited by 573
Self-citationProcessing of Structurally Heterogeneous Cryo-EM Data in RELION
Scheres, S. H. W. (2016) · Methods in Enzymology · doi:10.1016/bs.mie.2016.04.012 · Cited by 549
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
Huo, J., Le Bas, A., Ruza, R. R., Duyvesteyn, H. M. E., Mikolajek, H., Malinauskas, T., Tan, T. K., Rijal, P., Dumoux, M., Ward, P. N., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0469-6 · Cited by 500
Whitt, M. A. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.08.006 · Cited by 426
Sixteen novel lineages of SARS-CoV-2 in South Africa
Tegally, H., Wilkinson, E., Lessells, R. J., Giandhari, J., Pillay, S., Msomi, N., Mlisana, K., Bhiman, J. N., von Gottberg, A., Walaza, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01255-3 · Cited by 349
Five reasons why COVID herd immunity is probably impossible
Aschwanden, C. (2021) · Nature · doi:10.1038/d41586-021-00728-2 · Cited by 346
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
Rappazzo, C. G., Tse, L. V., Kaku, C. I., Wrapp, D., Sakharkar, M., Huang, D., Deveau, L. M., Yockachonis, T. J., Herbert, A. S., Battles, M. B., et al. (2021) · Science · doi:10.1126/science.abf4830 · Cited by 325
Self-citationBroad sarbecovirus neutralization by a human monoclonal antibody
Tortorici, M. A., Czudnochowski, N., Starr, T. N., Marzi, R., Walls, A. C., Zatta, F., Bowen, J. E., Jaconi, S., Di Iulio, J., Wang, Z., et al. (2021) · Nature · doi:10.1038/s41586-021-03817-4 · Cited by 266
Cathcart, A. L., Havenar-Daughton, C., Lempp, F. A., Ma, D., Schmid, M. A., Agostini, M. L., Guarino, B., Di iulio, J., Rosen, L. E., Tucker, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.09.434607 · Cited by 223
The effect of spike mutations on SARS-CoV-2 neutralization
Rees-Spear, C., Muir, L., Griffith, S. A., Heaney, J., Aldon, Y., Snitselaar, J. L., Thomas, P., Graham, C., Seow, J., Lee, N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108890 · Cited by 215
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients
Andreano, E., Nicastri, E., Paciello, I., Pileri, P., Manganaro, N., Piccini, G., Manenti, A., Pantano, E., Kabanova, A., Troisi, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.035 · Cited by 210
The SARS-CoV-2 Spike variant D614G favors an open conformational state
Mansbach, R. A., Chakraborty, S., Nguyen, K., Montefiori, D. C., Korber, B., & Gnanakaran, S. (2021) · Science Advances · doi:10.1126/sciadv.abf3671 · Cited by 206
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
Wang, L., Zhou, T., Zhang, Y., Yang, E. S., Schramm, C. A., Shi, W., Pegu, A., Oloniniyi, O. K., Henry, A. R., Darko, S., et al. (2021) · Science · doi:10.1126/science.abh1766 · Cited by 206
Self-citationEngineering SARS-CoV-2 using a reverse genetic system
Xie, X., Lokugamage, K. G., Zhang, X., Vu, M. N., Muruato, A. E., Menachery, V. D., & Shi, P.-Y. (2021) · Nature Protocols · doi:10.1038/s41596-021-00491-8 · Cited by 179
Self-citationImmunity to SARS-CoV-2 variants of concern
Altmann, D. M., Boyton, R. J., & Beale, R. (2021) · Science · doi:10.1126/science.abg7404 · Cited by 179
Kuzmina, A., Khalaila, Y., Voloshin, O., Keren-Naus, A., Boehm-Cohen, L., Raviv, Y., Shemer-Avni, Y., Rosenberg, E., & Taube, R. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.008 · Cited by 179
Tada, T., Dcosta, B. M., Samanovic, M. I., Herati, R. S., Cornelius, A. R., Zhou, H., Vaill, A., Kazmierski, W., Mulligan, M. J., & Landau, N. R. (2021) · mBio · doi:10.1128/mbio.00696-21 · Cited by 160
Emergence of a Highly Fit SARS-CoV-2 Variant
Baric, R. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmcibr2032888 · Cited by 153
The emerging plasticity of SARS-CoV-2
McCormick, K. D., Jacobs, J. L., & Mellors, J. W. (2021) · Science · doi:10.1126/science.abg4493 · Cited by 140
Neutralizing antibodies for the treatment of COVID-19
Jiang, S., Zhang, X., Yang, Y., Hotez, P. J., & Du, L. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00660-2 · Cited by 118
Santos, J. C., & Passos, G. A. S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.29.424708 · Cited by 95
Covid-19: variants and vaccination
Darby, A. C., & Hiscox, J. A. (2021) · BMJ · doi:10.1136/bmj.n771 · Cited by 77
Cerutti, G., Rapp, M., Guo, Y., Bahna, F. A., Bimela, J. S., Reddem, E. R., Yu, J., Wang, P., Liu, L., Huang, Y., et al. (2021) · Structure · doi:10.1016/j.str.2021.05.014 · Cited by 59
Self-citationRapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing
Lieu, R., Antonysamy, S., Druzina, Z., Ho, C., Kang, N. R., Pustilnik, A., Wang, J., & Atwell, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232311 · Cited by 45
Self-citationStructural basis for broad sarbecovirus neutralization by a human monoclonal antibodyPreprint
Tortorici, M. A., Czudnochowski, N., Starr, T. N., Marzi, R., Walls, A. C., Zatta, F., Bowen, J. E., Jaconi, S., di Iulio, J., Wang, Z., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.07.438818 · Cited by 22
Research works printed but not linked: 3
- Jones, 2020, LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection, bioRxiv
- Lieu, 2020, Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing, Plos One, 15, e0232311, 10.1371/journal.pone.0232311 · DOI
- Yao, 2021, Spike mutations decrease SARS-CoV-2 sensitivity to neutralizing antibodies but not ACE2-Ig in vitro, bioRxiv
Cited by
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04980-y · Cited by 1,335
Self-citationAlarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Wang, Q., Iketani, S., Li, Z., Liu, L., Guo, Y., Huang, Y., Bowen, A. D., Liu, M., Wang, M., Yu, J., et al. (2023) · Cell · doi:10.1016/j.cell.2022.12.018 · Cited by 912
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution
Cao, Y., Jian, F., Wang, J., Yu, Y., Song, W., Yisimayi, A., Wang, J., An, R., Chen, X., Zhang, N., et al. (2023) · Nature · doi:10.1038/s41586-022-05644-7 · Cited by 841
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
Wang, Q., Guo, Y., Iketani, S., Nair, M. S., Li, Z., Mohri, H., Wang, M., Yu, J., Bowen, A. D., Chang, J. Y., et al. (2022) · Nature · doi:10.1038/s41586-022-05053-w · Cited by 775
SARS-CoV-2 Omicron variant: recent progress and future perspectives
Fan, Y., Li, X., Zhang, L., Wan, S., Zhang, L., & Zhou, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00997-x · Cited by 589
Metadata
- Authors
- Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., Sauder, J. M., Kraft, L., Hwang, Y., Siegel, R. W., Chen, J., Heinz, B. A., Higgs, R. E., Kallewaard, N. L., Jepson, K., Goya, R., Smith, M. A., Collins, D. W., Pellacani, D., Xiang, P., de Puyraimond, V., Ricicova, M., Devorkin, L., Pritchard, C., O’Neill, A., Dalal, K., Panwar, P., Dhupar, H., Garces, F. A., Cohen, C. A., Dye, J. M., Huie, K. E., Badger, C. V., Kobasa, D., Audet, J., Freitas, J. J., Hassanali, S., Hughes, I., Munoz, L., Palma, H. C., Ramamurthy, B., Cross, R. W., Geisbert, T. W., Menachery, V., Lokugamage, K., Borisevich, V., Lanz, I., Anderson, L., Sipahimalani, P., Corbett, K. S., Yang, E. S., Zhang, Y., Shi, W., Zhou, T., Choe, M., Misasi, J., Kwong, P. D., Sullivan, N. J., Graham, B. S., Fernandez, T. L., Hansen, C. L., Falconer, E., Mascola, J. R., Jones, B. E., & Barnhart, B. C.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 39
- Issue
- 7
- Pages
- 110812
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W4225647476
- Cited by
- 414
- References
- 64
- FWCI
- 44.23
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Argonne National Laboratory (DE-AC02-06CH11357)
- U.S. Department of Energy
- Defense Advanced Research Projects Agency Defense Sciences Office (D18AC00002)
- National Institute of Allergy and Infectious Diseases
- University of Texas Medical Branch
- Defense Advanced Research Projects Agency
- Horizon 2020 Framework Programme
- Eli Lilly and Company
- Vaccine Research Center
- Office of Science
- U.S. Department of Defense
- Horizon 2020 (653316)
- National Institutes of Health (UC7AI094660)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.